Newsroom 2016-11-07T21:10:01+00:00


  • Name

    Center for Inherited Blood Disorders (CIBD)

  • Purpose

    CIBD is the federally-recognized hemophilia treatment center (HTC) for Orange, San Bernardino and Riverside counties, and parts of Los Angeles County. As one of over 130 non-profit centers nationwide recognized by the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA), and the Centers for Disease Control and Prevention (CDC), CIBD’s hematology specialists collaborates with doctors, clinics, and hospitals to provide comprehensive care to children, teens, and adults with inherited blood disorders

  • Founder

    Diane Nugent, M.D.

    Read Bio
  • Diseases Treated

  • Bleeding disorders such as hemophilia and von Willebrand disease
  • Anemias such as sickle cell disease or hemoglobin disorders
  • Thalassemia and other inherited anemias
  • Inherited excessive clotting disorders or thrombophilia
  • Services

Provides education, support, and services to children, teens, and adults with rare inherited blood disorders, and their families. Team of professionals includes adult hematologists, pediatric hematologists, nurses, physical therapist, clinical pharmacist, and social worker.
Coordinates hematology diagnosis and care for all blood disorders such as Sickle cell disease, anemias, women and bleeding, hemophilia, and excessive clotting problems. Includes coordination of care with dentists, genetic counselors, obstetrician/gynecologists, primary care practitioners, and school nurses.
A non-profit 340B pharmacy owned and operated by CIBD, is able to purchase clotting factor and other specialized medicine at a discounted rate, passing the savings onto patients, and healthcare providers.
Serve to inform medical professionals about the latest in bleeding disorders.
Is CIBD’s way of recognizing outstanding college students who are being treated at CIBD
  • Service Area

  • Orange County
  • Riverside County
  • San Bernardino County
  • parts of Los Angeles County
  • Honors


    340B Peer-to-Peer Program Leading Practice Site
    CIBD was named by the Health Resources & Services Administration’s Office of Pharmacy Affairs as a Leading Practice Site in the 340B Peer-to-Peer Program, marking the first time that an HTC has received this distinction, and making CIBD the only Leading Practice Site in California. See news release.

  • Funding

    CIBD receives federal funding from the U.S. Department of Health and Human Services—Health Resources and Services Administration Maternal and Child Health Bureau, and the Centers for Disease Control and Prevention. Other funding sources include grants and private donors.

  • Oversight

    CIBD adheres to the federal guidelines of delivering comprehensive hemophilia services of the following organizations.

  • Centers for Disease Control and Prevention
  • U.S. Department of Health and Human Services—Health Resources & Services Administration Maternal and Child Health Bureau
  • National Hemophilia Foundation
  • Partners

    CIBD works in partnership with the following organizations to mutually advance the mission of each organization

  • Alliance for Integrated Medication Management
  • American Red Cross
  • Coalition of Orange County Community Centers
  • National Center for Health Statistics
  • National Institutes of Health
  • Patient Safety & Clinical Pharmacy Services Collaboration
  • Sickle Cell Disease Foundation of California
  • Western States/Region IX

    For the purpose of accountability and sharing resources, HTC facilities in the United States are organized into regions. CIBD is part of the Western States (California, Hawaii, Nevada, and Guam)/Region IX made up of 14 HTC facilities serving over 5,600 residents.

  • Statistics

    In the United States:

  • Hemophilia affects 1 in 5,000 male births.
  • About 400 babies are born with hemophilia each year.
  • About 20,000 people live with hemophilia in the United States